Legend Biotech (LEGN) Receivables - Net (2019 - 2026)
Legend Biotech's (LEGN) quarterly Receivables - Net came in at $1.7 million in Q1 2026, up 360.7% YoY from $369000.0 in Q1 2025, and down 87.02% on a QoQ basis from $13.1 million in Q4 2025.
Legend Biotech (LEGN) Receivables - Net (2019 - 2026) Analysis & Trends
Legend Biotech (LEGN) has 8 years of Receivables - Net data on file, last reported at $1.7 million in Q1 2026.
- Quarterly Receivables - Net rose 360.7% year-over-year to $1.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.7 million (up 360.7% YoY) and the FY2025 annual result came in at $13.1 million, up 104.69% from the prior year.
- Receivables - Net eased to $1.7 million in Q1 2026, from $13.1 million in the prior quarter.
- In the past five years, Receivables - Net ranged from a high of $100.0 million in Q4 2023 to a low of $20000.0 in Q3 2023.
- A 5-year average of $15.5 million and a median of $3.3 million in 2024 frame the typical range for Receivables - Net.
- The widest YoY moves for Receivables - Net: up 111056.67% in 2023, down 99.89% in 2023.
- Tracing LEGN's Receivables - Net over 5 years: stood at $90000.0 in 2022, then surged by 111056.67% to $100.0 million in 2023, then plunged by 93.6% to $6.4 million in 2024, then soared by 104.69% to $13.1 million in 2025, then slumped by 87.02% to $1.7 million in 2026.
- The last three Receivables - Net figures came in at $1.7 million (Q1 2026), $13.1 million (Q4 2025), and $1.2 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Legend Biotech | 3.95 Bn | 3.27 Bn | 251.50 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 1.70 Mn |
| Mar 31, 2026 | 1.70 Mn |
| Dec 31, 2025 | 13.10 Mn |
| Dec 31, 2025 | 13.10 Mn |
| Sep 30, 2025 | 1.24 Mn |
| Sep 30, 2025 | 1.24 Mn |
| Jun 30, 2025 | 27.58 Mn |
| Jun 30, 2025 | 27.58 Mn |
| Mar 31, 2025 | 369,000.00 |
| Mar 31, 2025 | 369,000.00 |
| Dec 31, 2024 | 6.40 Mn |
| Dec 31, 2024 | 6.40 Mn |
| Sep 30, 2024 | 705,000.00 |
| Sep 30, 2024 | 705,000.00 |
| Jun 30, 2024 | 13.06 Mn |
| Jun 30, 2024 | 13.06 Mn |
| Mar 31, 2024 | 3.31 Mn |
| Mar 31, 2024 | 3.31 Mn |
| Dec 31, 2023 | 100.04 Mn |
| Dec 31, 2023 | 100.04 Mn |